UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data
April 16, 2014 at 09:29 AM EDT
In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on ImmunoGen (NASDAQ: IMGN) with a Buy rating ...